NASDAQ:NAGE

Niagen Bioscience Q3 2026 Earnings Results & Report

Niagen Bioscience logo
$1.82 -0.06 (-2.94%)
As of 03:26 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Niagen Bioscience met analyst earnings expectations in its Q3 2026 results, released November 4, 2026. The company reported EPS of -$0.01 versus the -$0.01 consensus estimate, while revenue was $27.19 million.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
After Market Closes

Niagen Bioscience EPS Results

Actual EPS
-$0.01
Consensus EPS
-$0.01
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Niagen Bioscience Revenue Results

Actual Revenue
$27.19 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Niagen Bioscience Q3 2026 Earnings FAQ

Niagen Bioscience (NASDAQ:NAGE) reported earnings of -$0.01 per share for Q3 2026, matching the consensus estimate of -$0.01. The report was announced on Wednesday, November 4, 2026.

Niagen Bioscience reported revenue of $27.19 million for Q3 2026.

Niagen Bioscience Earnings Headlines

Earn $4,500 a month? Your income may count for more
Earn $4,500 or more a month? Pennie lets you explore personal loan options that consider your income, not just your credit score. Options include personal loans up to $250,000 and APRs starting at 5.99%. Checking your rate is free, and the soft credit check won't affect your score. Pennie is a loan marketplace, not a lender. Offers come from third-party partners and are not guaranteed.tc pixel
See More Niagen Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Niagen Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Niagen Bioscience and other key companies, straight to your email.

About Niagen Bioscience

Niagen Bioscience (NASDAQ:NAGE) develops and markets products based on nicotinamide riboside (NR), a form of vitamin B3 studied for its role in supporting the body’s production of NAD+. Its offerings include Tru Niagen, a consumer dietary supplement, and Niagen, a branded NR ingredient supplied to other businesses.

The company also conducts and supports research on NR, NAD+ and healthy aging. It was formerly known as ChromaDex Corporation and adopted the Niagen Bioscience name in 2025.

Niagen Bioscience serves consumers and commercial customers in the United States and international markets through online sales, retail and distribution channels. Rob Fried is the company’s chief executive officer.

View Niagen Bioscience Profile